Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0148
-0.0002 (-1.33%)
Jan 21, 2026, 3:52 PM CET
-89.69%
Market Cap9.09M
Revenue (ttm)1.32M
Net Income (ttm)-35.97M
Shares Out605.93M
EPS (ttm)-0.14
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume747,830
Average Volume6,561,859
Open0.0150
Previous Close0.0150
Day's Range0.0128 - 0.0160
52-Week Range0.0072 - 0.3695
Beta0.60
RSI32.94
Earnings DateFeb 20, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 7
Stock Exchange Nasdaq Stockholm
Ticker Symbol LPGO
Full Company Profile

Financial Performance

In 2024, STO:LPGO's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.

Financial Statements